Biotechnology
Biopharmaceutical
Pharmaceutical

Intercept Pharmaceuticals

$111.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.01 (1.84%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ICPT and other stocks, options, ETFs, and crypto commission-free!

About

Intercept Pharmaceuticals, Inc. Common Stock, also called Intercept Pharmaceuticals, is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Read More Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Employees
483
Headquarters
New York, New York
Founded
2002
Market Cap
3.25B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
672.39K
High Today
$111.88
Low Today
$109.45
Open Price
$110.52
Volume
124.33K
52 Week High
$133.74
52 Week Low
$58.03

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Research And Development
Technology

News

MarketBeatMar 14

Stock Price, News, & Analysis for Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH)...

28
Yahoo FinanceMar 6

Edited Transcript of ICPT earnings conference call or presentation 28-Feb-19 1:30pm GMT

Q4 2018 Intercept Pharmaceuticals Inc Earnings Call New York Mar 7, 2019 (Thomson StreetEvents) -- Edited Transcript of Intercept Pharmaceuticals Inc earnings conference call or presentation Thursday, February 28, 2019 at 1:30:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * Jerome B. Durso Int...

54
The Motley FoolMar 6

Why Intercept Pharmaceuticals Stock Hit the Skids in February

What happened Intercept Pharmaceuticals (NASDAQ:ICPT), a mid-cap drugmaker focusing on diseases of the liver, saw its shares lose 14.5% of their value last month, according to data from S&P Global Market Intelligence. Prior to last month's pullback, Intercept's shares were up by almost 80% over the last 12 months. So what halted Intercept's protracted rally? On Feb. 19 the company reported positive top-line results for obeticholic acid (Ocaliva) in patients with liver fibrosis due to nonalcoholic steatohe...

138

Earnings

-$4.43
-$3.68
-$2.93
-$2.18
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.